Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Gross Profit (2016 - 2025)

Historic Gross Profit for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $143.8 million.

  • Myriad Genetics' Gross Profit fell 400.53% to $143.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $580.7 million, marking a year-over-year increase of 1242.98%. This contributed to the annual value of $585.4 million for FY2024, which is 1323.02% up from last year.
  • As of Q3 2025, Myriad Genetics' Gross Profit stood at $143.8 million, which was down 400.53% from $151.8 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Gross Profit ranged from a high of $151.8 million in Q2 2025 and a low of $59.1 million during Q4 2022
  • Its 5-year average for Gross Profit is $126.1 million, with a median of $129.6 million in 2022.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 13180.33% in 2021, then tumbled by 4860.87% in 2022.
  • Myriad Genetics' Gross Profit (Quarter) stood at $115.0 million in 2021, then crashed by 48.61% to $59.1 million in 2022, then skyrocketed by 38.75% to $82.0 million in 2023, then soared by 84.02% to $150.9 million in 2024, then decreased by 4.71% to $143.8 million in 2025.
  • Its Gross Profit was $143.8 million in Q3 2025, compared to $151.8 million in Q2 2025 and $134.2 million in Q1 2025.